Expanding Access to Remdesivir via an Improved Pyrrolotriazine Synthesis: Supply Centered Synthesis
- PMID: 32931286
- PMCID: PMC7536717
- DOI: 10.1021/acs.orglett.0c02848
Expanding Access to Remdesivir via an Improved Pyrrolotriazine Synthesis: Supply Centered Synthesis
Abstract
Pyrrolotriazine 1 is an important precursor to remdesivir. Initial results toward an efficient synthesis are disclosed consisting of sequential cyanation, amination, and triazine formation beginning from pyrrole. This route makes use of highly abundant, commoditized raw material inputs. The yield of triazine was doubled from 31% to 59%, and the synthetic step count was reduced from 4 to 2. These efforts help to secure the remdesivir supply chain.
Conflict of interest statement
The authors declare no competing financial interest.
Figures






References
-
- Mullin R.COVID-19 is reshaping the pharmaceutical supply chain, Chem. Eng. News, 2020, 98.
- Mullin R.Bringing drug production back to the US. Chem. Eng. News, 2020, 98.
- Woodcock J.; Safeguarding Pharmaceutical Supply Chains in a Global Economy; U.S. Food and Drug Administration. https://www.fda.gov/news-events/congressional-testimony/safeguarding-pha... (Accessed July 10, 2020).
-
-
For examples see Gilead company statements:
- An Update on COVID-19 from our Chairman & CEO; Gilead Sciences, Inc. https://stories.gilead.com//articles/an-update-on-covid-19-from-our-chai... (Accessed July 1, 2020).
- An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences; Gilead Sciences, Inc. https://www.gilead.com/news-and-press/press-room/press-releases/2020/6/a... (Accessed July 1, 2020).
- Trump Administration Secures New Supplies of Remdesivir for the United States; U.S. Department of Health and Human Services. https://www.hhs.gov/about/news/2020/06/29/trump-administration-secures-n... (Accessed July 10, 2020).
-
-
- Siegel D.; Hui H. C.; Doerffler E.; Clarke M. O.; Chun K.; Zhang L.; Neville S.; Carra E.; Lew W.; Ross B.; Wang Q.; Wolfe L.; Jordan R.; Soloveva V.; Knox J.; Perry J.; Perron M.; Stray K. M.; Barauskas O.; Feng J. Y.; Xu Y.; Lee G.; Rheingold A. L.; Ray A. S.; Bannister R.; Strickley R.; Swaminathan S.; Lee W. A.; Bavari S.; Cihlar T.; Lo M. K.; Warren T. K.; Mackman R. L. J. Med. Chem. 2017, 60, 1648–1661. 10.1021/acs.jmedchem.6b01594. - DOI - PubMed
- De Savi C.; Hughes D. L.; Kvaerno L. Org. Process Res. Dev. 2020, 24, 940–976. 10.1021/acs.oprd.0c00233. - DOI - PubMed
- Vieira T.; Stevens A. C.; Chtchemelinine A.; Gao D.; Badalov P.; Heumann L.. Org. Process Res. Dev. 2020, ASAP.10.1021/acs.oprd.0c00172. - DOI - PubMed
-
- Snead D. R.; McQuade D. T.; Ahmad S.; Krack R.; Stringham R. W.; Burns J. M.; Abdiaj I.; Gopalsamuthiram V.; Nelson R. C.; Gupton B. F. Org. Process Res. Dev. 2020, 24, 1194–1198. 10.1021/acs.oprd.0c00083. - DOI - PMC - PubMed
- Kashinath K.; Snead D. R.; Burns J. M.; Stringham R. W.; Gupton B. F.; McQuade D. T. M.. Org. Process Res. Dev. 2020, ASAP.10.1021/acs.oprd.0c00145. - DOI - PMC - PubMed
-
- Dixon J. A.; Phillips B.; Achebe F.; Kluender H. C. E.; Newcom J.; Parcella K.; Magnuson S.; Hong Z.; Zhang Z.; Liu Z.; Khire U.; Wang L.; Michels M.; Chandler B.; O’Connor S.. US 8143393, 2006.
- O’Connor S.; Dumas J.; Lee W.; Dixon J.; Cantin D.; Gunn D.; Burke J.; Phillips B.; Lowe D.; Shelekhin T.; Wang G.; Ma X.; Ying S.; McClure A.; Achebe F.; Lobell M.; Ehrgott F.; Iwuagwu C.; Parcella K.. US 8431695, 2006.
LinkOut - more resources
Full Text Sources
Other Literature Sources